Details of the Drug Combination

General Information of Drug Combination (ID: DCFVBUO)

Drug Combination Name

Amonafide Terameprocol

Indication

Disease Entry	Status	REF
Breast adenocarcinoma	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Terameprocol DMC3P45

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: MDA-MB-468

Zero Interaction Potency (ZIP) Score: 1.12

Bliss Independence Score: 1.74

Loewe Additivity Score: 0.17

LHighest Single Agent (HSA) Score: 2.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Amonafide

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[3]
------------------------------------------------------------------------------------

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.